Novartis Selects Qualcomm Lifes 2net Tech to Digitize Clinical Trials
Qualcomm announced that its subsidiary, Qualcomm Life, has been selected by Novartis as a global digital health collaborator for its Trials of The Future program.
Qualcomm announced that its subsidiary, Qualcomm Life, has been selected by Novartis as a global digital health collaborator for its Trials of The Future program. Qualcomm Life’s 2net Platform will serve as a global connectivity platform for collecting and aggregating medical device data during clinical trials to improve the convenience and speed of capturing study participant data and test results to ultimately gain more trial efficiencies and connected experiences for participants.
The Trials of The Future program is designed to leverage health care technology to improve the experience of clinical trial participants and patients using Novartis products, and provide connectivity with future products marketed by Novartis. Novartis is using the 2net Platform in a recently-launched observational study, evaluating the use of mobile devices with chronic lung disease patients. In this trial, 2net Mobile-enabled smartphones and 2net Hubs collect and aggregate biometric data from medical devices and transmits data to the cloud-based 2net Platform, which securely sends the data to the study coordinator.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
